Urothelial Carcinoma of the Bladder
6
2
3
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 6 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 3 completed trials
Clinical Trials (6)
Perioperative Systemic Therapies in Muscle-Invasive Bladder Cancer (GUARDIANS)
Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)
Association Between Irrigation Fluid Absorption and Perioperative cfDNA Dynamics After TURBT
AN0025 and Pembrolizumab Combination in Advanced Solid Tumors
Initial Evaluation of a Telomerase-based Circulating Tumor Cell Assay in Bladder Cancer Cohorts
Adjuvant Proton Therapy or IMRT for the Treatment of Bladder Cancer